Autres langues Innovent Biologics, Inc.

Actions

1801

KYG4818G1010

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:09 16/05/2024			Varia. 5j.	Varia. 1 janv.
39,8 ^HKD	+0,89 %		-1,85 %	-6,90 %

07/05	Innovent reçoit la désignation de NMPA Breakthrough Therapy pour IBI343 (ADC Anti-Claudin18.2) en tant que monothérapie pour le cancer gastrique avancé	CI
30/04	Innovent Biologics, Inc. nomme Samuel Zhang au poste de Global Chief Business Officer	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Head-to-head Superiority to High-dose Dulaglutide, Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints	10/05
Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC) as Monotherapy for Advanced Gastric Cancer	07/05
Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer	01/05
Innovent Biologics, Inc. Reports Revenue Results for the First Quarter of 2024	30/04
Innovent Biologics, Inc. Appoints Samuel Zhang as Global Chief Business Officer	30/04
Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17/04
Innovent Appoints Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer	17/04
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03/04
Hutchmed endometrial cancer treatment application accepted for review	02/04
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	02/04
HSBC in special payout on Canada sale; Astra FDA win	02/04
Innovent Biologics New Cancer Drug Gets NDA from Chinese Authority	02/04
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	02/04
Innovent Biologics, Inc. Announces the National Medical Products Administration Accepts the New Drug Application	02/04
Innovent Biologics' Loss Narrows in 2023 as Revenue Grows	21/03
Innovent Biologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Innovent Biologics, Inc. Releases the Results of Two Clinical Studies of Ibi311 (An Anti-IGF-1R Monoclonal Antibody) in Oral Presentations At the Asia-Pacific Academy of Ophthalmology Congress and International Congress of Endocrinology 2024	07/03
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer	06/03
China Accepts Innovent's Second Drug Application for Lung Cancer Treatment; Shares Slide 6%	05/03
Anheart Therapeutics and Innovent Announces China?s NMPA Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of Ros1-Positive Lung Cancer	05/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Innovent Biologics, Inc.

Actions

1801

KYG4818G1010

Autres langues

Filtres